TerminatedPhase 3NCT03763422
Trial in Low Grade Glioma Patients: Wait or Treat
Studying Glial tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Martin Van den BentEORTC Study Coordinator
- Intervention
- Temozolomide(drug)
- Enrollment
- 19 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2021
Study locations (30)
- Princess Alexandra Hospital - University of Queensland, Woolloongabba, Brisbane, QLD, Australia
- Prince of Wales Hospital, Randwick - Sydney, New South Wales, Australia
- Westmead Hospital - Crown Princess Mary Cancer Centre, Westmead, New South Wales, Australia
- Illawarra Cancer Care Centre - Wollongong Hospital, Wollongong, New South Wales, Australia
- Royal Adelaide Hospital, Adelaide, South Australia, Australia
- Royal Hobart Hospital, Hobart, Tasmania, Australia
- Monash Medical Centre, Clayton, Victoria, Australia
- St Vincent's Hospital, Fitzroy (Melbourne), Victoria, Australia
- Austin Hospital, Heidelberg, Victoria, Australia
- Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
- Universitaetskliniken der Uni Wien - Universitaetsklinikum Wien - AKH uniklinieken, Vienna, Austria
- Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium
- Gasthuiszusters van Antwerpen - GasthuisZusters Antwerpen - Sint-Augustinus, Wilrijk, Belgium
- Aarhus University Hospitals - Aarhus University Hospital-Skejby, Aarhus, Denmark
- CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer, Bron, France
- +15 more locations on ClinicalTrials.gov
Collaborators
Cooperative Trials Group for Neuro-Oncology (COGNO)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03763422 on ClinicalTrials.govOther trials for Glial tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07210632Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)Eben Rosenthal
- RECRUITINGNCT07236840Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain TumorsTata Memorial Centre
- RECRUITINGNCT07240662Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse GliomaiOMEDICO AG
- RECRUITINGNCT07405372Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of GliomasDaping Hospital and the Research Institute of Surgery of the Third Military Medical University
- RECRUITINGPHASE2NCT07110246Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasUniversity of California, San Francisco
- RECRUITINGPHASE1NCT07223034A Study of 177Lu-PSMA-617 in People With GliomasMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGNCT07238322[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related ChangesTelix Pharmaceuticals (Innovations) Pty Limited
- RECRUITINGNANCT06397560PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies TrialBaptist Health South Florida